These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 34565137)
41. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. Rao H; Song G; Li G; Yang Y; Wu X; Guan Y; Mao Q; Jiang X; Wang C; Zhang Y; Jia J; Guo X; Li C; Ning J; Qin H; Pan H; Wei L J Viral Hepat; 2020 Jan; 27(1):45-51. PubMed ID: 31520460 [TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136 [TBL] [Abstract][Full Text] [Related]
43. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906 [TBL] [Abstract][Full Text] [Related]
44. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. Bailly F; Pradat P; Virlogeux V; Zoulim F Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282 [TBL] [Abstract][Full Text] [Related]
45. Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. Sanai FM; Altraif IH; Alswat K; AlZanbagi A; Babatin MA; AlMousa A; Almutairi NH; Aljawad MS; Alghamdi AS; Aljumah AA; Alalwan AM; Al-Hamoudi WK; Assiri AM; Dahlan Y; Alsahafi A; Alothmani HS; AlSaleemi MS; Mousa WA; Albenmousa A; Awny A; Albiladi H; Abdo AA; AlGhamdi H J Infect; 2018 Jun; 76(6):536-542. PubMed ID: 29742470 [TBL] [Abstract][Full Text] [Related]
46. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil. Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742 [TBL] [Abstract][Full Text] [Related]
47. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072 [TBL] [Abstract][Full Text] [Related]
48. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960 [TBL] [Abstract][Full Text] [Related]
49. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Flisiak R; Flisiak-Jackiewicz M Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):559-567. PubMed ID: 28317409 [TBL] [Abstract][Full Text] [Related]
50. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347 [TBL] [Abstract][Full Text] [Related]
51. Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment. McKnight AH; Townsend ML; Hashem MG; Naggie S; Park LP; Britt RB Ann Pharmacother; 2020 Nov; 54(11):1057-1064. PubMed ID: 32406244 [TBL] [Abstract][Full Text] [Related]
52. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Mettikanont P; Bunchorntavakul C; Reddy KR Aliment Pharmacol Ther; 2019 Mar; 49(5):492-505. PubMed ID: 30687952 [TBL] [Abstract][Full Text] [Related]